Daniel J. George, MD, says that clinicians who treat prostate cancer have devoted the past 70 years to hormone therapy and androgen deprivation therapy, particularly for patients with metastatic disease. However, the emergence of agents like docetaxel, abiraterone acetate, and androgen receptor antagonists, like apalutamide and enzalutamide, have changed the landscape.<br />
Daniel J. George, MD, medical oncologist, Duke Cancer Institute, says that clinicians who treat prostate cancer have devoted the past 70 years to hormone therapy and androgen deprivation therapy, particularly for patients with metastatic disease. However, the emergence of agents like docetaxel, abiraterone acetate (Zytiga), and androgen receptor (AR) antagonists, like apalutamide (Erleada) and enzalutamide (Xtandi), have changed the landscape.
Now that clinical studies have shown how all of these agents can benefit patients with prostate cancer, oncologists will have the opportunity to use some agents earlier and combinations with novel agents to increase benefit in the post-AR and post-chemotherapy settings. The number of possibilities is making room for more clinical trials that will help to prolong life in patients with prostate cancer.
The most exciting thing about the evolving landscape is that some of these agents will move on into the curative setting, says George.
Brain Cancer Awareness Month: Challenges and Innovations in Treatment
May 13th 2024In an interview with Targeted Oncology for Brain Cancer Awareness Month, Theodore Schwartz, MD, discussed the challenges of targeting brain tumors, emerging therapies, and strategies to overcome the blood-brain barrier.
Read More
SELECT Trial Establishes Lenvatinib’s Role in RAI-Refractory DTC
May 2nd 2024In an interview with Targeted Oncology, Lori J. Wirth, MD, delved into how the data from SELECT signals lenvatinib effectiveness as a frontline therapy for patients with RAI-refractory differentiated thyroid cancer.
Read More